Cargando…
Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma.
From January 1983 to December 1986 seventy-six previously untreated children with non-Hodgkin's lymphoma (NHL) were treated by combination chemotherapy. Burkitt's lymphoma patients were ineligible. The treatment regimens include intermittent chemotherapy and for non-localized patients, pro...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1987
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001901/ https://www.ncbi.nlm.nih.gov/pubmed/3426926 |
_version_ | 1782135683464298496 |
---|---|
author | Büyükpamukçu, M. Sarialioğlu, F. Akyüz, C. Cevik, N. |
author_facet | Büyükpamukçu, M. Sarialioğlu, F. Akyüz, C. Cevik, N. |
author_sort | Büyükpamukçu, M. |
collection | PubMed |
description | From January 1983 to December 1986 seventy-six previously untreated children with non-Hodgkin's lymphoma (NHL) were treated by combination chemotherapy. Burkitt's lymphoma patients were ineligible. The treatment regimens include intermittent chemotherapy and for non-localized patients, prophylactic central nervous system chemotherapy. Intrathoracic non-Hodgkin's lymphoma patients also had cranial prophylactic radiotherapy. Sixty-six patients (86.8%) achieved complete remission. Two year failure-free survival rate was 82.1% for localized (stage I and II) NHL and 53.3% for non-localized (stage III and IV) NHL patients. Failure-free survival did not differ significantly for the two major histologic diagnoses, but two year survival rate was lower in diffuse poorly differentiated lymphoblastic than undifferentiated non-Burkitt's lymphoma (50% versus 66.8% respectively). Failure-free survival rate was 53.7% in mediastinal disease and, 73.2% in abdominal disease at 24 months. Relapse rate was higher in mediastinal cases (46.1%) than primary abdominal cases (24.3%) at 24 months. Eleven (13.5%) died of treatment related sepsis. Although the overall survival rate was 72.4% at 2 years we need novel or more intensive programmes for mediastinal and non-localized disease. |
format | Text |
id | pubmed-2001901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1987 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20019012009-09-10 Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. Büyükpamukçu, M. Sarialioğlu, F. Akyüz, C. Cevik, N. Br J Cancer Research Article From January 1983 to December 1986 seventy-six previously untreated children with non-Hodgkin's lymphoma (NHL) were treated by combination chemotherapy. Burkitt's lymphoma patients were ineligible. The treatment regimens include intermittent chemotherapy and for non-localized patients, prophylactic central nervous system chemotherapy. Intrathoracic non-Hodgkin's lymphoma patients also had cranial prophylactic radiotherapy. Sixty-six patients (86.8%) achieved complete remission. Two year failure-free survival rate was 82.1% for localized (stage I and II) NHL and 53.3% for non-localized (stage III and IV) NHL patients. Failure-free survival did not differ significantly for the two major histologic diagnoses, but two year survival rate was lower in diffuse poorly differentiated lymphoblastic than undifferentiated non-Burkitt's lymphoma (50% versus 66.8% respectively). Failure-free survival rate was 53.7% in mediastinal disease and, 73.2% in abdominal disease at 24 months. Relapse rate was higher in mediastinal cases (46.1%) than primary abdominal cases (24.3%) at 24 months. Eleven (13.5%) died of treatment related sepsis. Although the overall survival rate was 72.4% at 2 years we need novel or more intensive programmes for mediastinal and non-localized disease. Nature Publishing Group 1987-11 /pmc/articles/PMC2001901/ /pubmed/3426926 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Büyükpamukçu, M. Sarialioğlu, F. Akyüz, C. Cevik, N. Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. |
title | Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. |
title_full | Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. |
title_fullStr | Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. |
title_full_unstemmed | Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. |
title_short | Combined chemotherapy in 76 children with non-Hodgkin's lymphoma excluding Burkitt's lymphoma. |
title_sort | combined chemotherapy in 76 children with non-hodgkin's lymphoma excluding burkitt's lymphoma. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001901/ https://www.ncbi.nlm.nih.gov/pubmed/3426926 |
work_keys_str_mv | AT buyukpamukcum combinedchemotherapyin76childrenwithnonhodgkinslymphomaexcludingburkittslymphoma AT sarialiogluf combinedchemotherapyin76childrenwithnonhodgkinslymphomaexcludingburkittslymphoma AT akyuzc combinedchemotherapyin76childrenwithnonhodgkinslymphomaexcludingburkittslymphoma AT cevikn combinedchemotherapyin76childrenwithnonhodgkinslymphomaexcludingburkittslymphoma |